The OIG has added 18 reviews to its FY 2017 Work Plan – most of which target CMS programs, with a particular emphasis on prescription drug policies. For instance, the OIG now intends to examine the following Medicare and Medicaid topics (among others):

  • Excessive Use of Opioids in Medicare Part D
  • Including Non-Covered Versions When Setting Payment Amounts for Part B Drugs
  • FDA Approval Status of Drugs in the Medicaid Drug Rebate Program
  • Accuracy of Drug Classification Data Used to Collect Medicaid Rebates
  • Reasonable Assumptions in Manufacturer AMP Reporting
  • Review of Quality Measures Data Reported by Accountable Care Organizations in the Medicare Shared Savings Program
  • Trends in Hospice Deficiencies and Complaints

Additional information about each of the new reviews is available on the OIG website.

This article is presented for informational purposes only and is not intended to constitute legal advice.